Drugs / PEP07
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05983523 | Mar 2024 → Feb 2027 expected | metastatic neoplasm, neoplasm | PharmaEngine | Recruiting | No outcome recorded |
| Phase 1 | NCT05659732 | Jul 2023 → Dec 2026 expected | acute myeloid leukemia, mantle cell lymphoma | PharmaEngine | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-09-22 | PharmaEngine | Regulatory PharmaEngine announces TFDA approval of PEP07 Phase I clinical trial for solid tumor cancers pharmaengine.com ↗
PharmaEngine, Inc. (TWO:4162) announces TFDA has approved PEP07 Phase 1 clinical trial for solid tumor cancers. |
| 2023-06-14 | PharmaEngine | Regulatory PharmaEngine announces Phase I clinical study of PEP07 has been approved by Taiwan Food and Drug Administration (TFDA) pharmaengine.com ↗
PharmaEngine Inc. (4162.TWO) announces Phase 1 clinical study in hematological cancer (e.g., AML or MCL) of PEP07, our product under development, has been approved by Taiwan Food and Drug Administration (TFDA). |
| 2023-03-03 | PharmaEngine | Regulatory PharmaEngine announces Phase I clinical study of PEP07 has been approved by Australia HREC and acknowledged by Australia TGA pharmaengine.com ↗
PharmaEngine, Inc. (TWO:4162) announces PEP07 Phase I clinical trial in hematological cancers (e.g., AML or MCL) has been approved by Australia HREC (Human Research Ethics Committee, HREC) and acknowledged by Australia TGA (Therapeutic Goods Administration, TGA). |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEP07 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05659732 ↗ |
| Action | Inhibit | “PEP07 is a selective Chk1 inhibitor maleate drug” NCT05659732 ↗ |
| Modality | Small molecule | “small molecule inhibitor” NCT05983523 ↗ |
| Route | Oral | “PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally.” NCT05659732 ↗ |